Versant Ventures
-
Bio Startup Nexo Lands $60M to Climb to New Heights in Cancer Drug R&D
Nexo Therapeutics is developing cancer drugs that expand the scope of amino acids addressable by covalent chemistry. Versant Ventures founded the startup and led its Series A financing.
-
Scripps Spinout Belharra Unveils $130M to Catch Next Big Wave of Drug Discovery
Versant Ventures-backed Belharra Therapeutics has launched with $130 million in funding and a partnership with Roche subsidiary Genentech. The startup’s technology analyzes proteins in the context of the entire cell, enabling it to discover molecules that bind to targets previously deemed undruggable.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Versant-founded biotech Nested hatches with $90M and new take on cancer drugs
Nested Therapeutics uses computational techniques to map mutations and protein structures, identifying previously unseen places where a cancer drug can bind. The Versant Ventures-founded startup is now out of stealth with two programs on the path to the clinic.
-
New Versant Ventures startup goes ‘gutless’ for next-generation gene delivery
Vector BioPharma has launched from the biotech startup incubator of Versant Ventures, which is backing the company with a $30 million Series A financing. Vector is developing virus-like particles with the capability to deliver large payloads of genetic medicines to a wide range of tissues.
-
A biotech’s bold vision to turn stem cell transplants into outpatient procedures
Versant Ventures has launched Cimeio Therapeutics, a biotech startup with technology that can shield transplanted stem cells or cell therapies. Shielding these cells enables them to be dosed alongside an immunotherapy—an approach that is not currently done because the therapies don’t discriminate between diseased cells and transplanted ones.
-
Tentarix Bio unveils $50M for biologics with multiple functions, multiple targets
Biotech startup Tentarix Biotherapeutics has come out of stealth with $50 million and technology that develops biologic drugs endowed with multiple functions. The company aims to develop new multispecific biologic drugs for cancer and autoimmune diseases.
-
Versant Ventures unveils new startup that stabilizes proteins to treat disease
Stablix Therapeutics is developing technology that uses small molecules to stabilize a protein, keeping it from going to a cell’s built-in disposal system. The startup now has $63 million in funding to further invest in the technology and advance its first molecules toward the clinic.
-
Monte Rosa raises $96M Series B for drug development platform technology
The Boston-based company plans to develop small-molecule therapeutics that go after historically “undruggable” targets using a process known as protein degradation.
-
Black Diamond, targeting untapped cancer mutations, files for $100M IPO
Just a little over a year after it emerged from stealth mode, the company – which recently initiated a clinical trial of a drug targeting allosteric mutations in solid tumors – has filed to go public.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Black Diamond Therapeutics raises $85M in Series B funding
The raise comes a month after the Cambridge, Massachusetts-based firm’s launch with a $20 million Series A round. Black Diamond is developing drugs that target allosteric mutant oncogenes, which it describes as an unexplored space.
-
Versant raises $100M for new Canada fund on top of $600M for global biotech startups
The firm said both funds exceeded their initial targets. Versant plans to use Fund VII for at least 20 global biotech companies, while Versant Voyageurs I will be used to fund five to eight startups with Canadian operations.
-
Versant launches Black Diamond Therapeutics with $20M to pursue untapped cancer mutations
The company plans to file an IND for its allosteric HER2-targeting drug at the end of 2019, followed by one for its second product candidate in the first half of 2020.
-
Preclinical startup Jecure makes bee-line to exit with Genentech buyout
Venture capital firm Versant Ventures launched the company with a $20 million Series A funding round last year.
-
RNA metabolism-focused Gotham Therapeutics launches with $54M Series A round
The company, focused on epitranscriptomics, launched with backing from Versant Ventures, Forbion, GSK’s venture capital arm, Celgene and others.
-
Therachon raises $60 million in mezzanine financing for rare disease drugs
The Basel, Switzerland-based biotech company plans to trial the drug in achondroplasia patients next year.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
